It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A comprehensive examination of protein-protein interactions (PPIs) is fundamental for the understanding of cellular machineries. However, limitations in current methodologies often prevent the detection of PPIs with low abundance proteins. To overcome this challenge, we develop a mRNA display with library of even-distribution (md-LED) method that facilitates the detection of low abundance binders with high specificity and sensitivity. As a proof-of-principle, we apply md-LED to IAV NS1 protein. Complementary to AP-MS, md-LED enables us to validate previously described PPIs as well as to identify novel NS1 interactors. We show that interacting with FASN allows NS1 to directly regulate the synthesis of cellular fatty acids. We also use md-LED to identify a mutant of NS1, D92Y, results in a loss of interaction with CPSF1. The use of high-throughput sequencing as the readout for md-LED enables sensitive quantification of interactions, ultimately enabling massively parallel experimentation for the investigation of PPIs.
Identification of low abundance proteins interacting with viral proteins can be challenging. Here, Du et al. develop an mRNA display approach with a library of even distribution, identify host proteins interacting with NS1 protein of influenza A virus, and show that one interactor provides a means to regulate cellular fatty acids synthesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of California, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); School of Medicine, Zhejiang University, Cancer Institute, ZJU-UCLA Joint Center for Medical Education and Research, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
2 University of California, San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, California Institute for Quantitative Biosciences, QB3, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); J. David Gladstone Institutes, San Francisco, USA (GRID:grid.249878.8) (ISNI:0000 0004 0572 7110); Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
3 University of California, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
4 University of California, Department of Molecular and Medical Pharmacology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Molecular Biology Institute, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
5 School of Medicine, Zhejiang University, Cancer Institute, ZJU-UCLA Joint Center for Medical Education and Research, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
6 University of California, San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, San Francisco, California Institute for Quantitative Biosciences, QB3, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); J. David Gladstone Institutes, San Francisco, USA (GRID:grid.249878.8) (ISNI:0000 0004 0572 7110)
7 Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
8 David Geffen School of Medicine at UCLA, L, Department of Pathology and Laboratory Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)